Compositions and methods related to engineered Fc constructs

26-03-2019 дата публикации

Номер:

US10239944B2

Автор: BOSQUES CARLOS J, HUSTON JAMES S, LANSING JONATHAN C, LING LEONA E, MEADOR III JAMES, ORTIZ DANIEL, RUTITZKY LAURA, Bosques, Carlos J., Huston, James S., Lansing, Jonathan C., Ling, Leona E., Meador, III, James, Ortiz, Daniel, Rutitzky, Laura

Принадлежит: MOMENTA PHARMACEUTICALS INC, Momenta Pharmaceuticals, Inc.

Контакты:

Номер заявки: 14-15-20161413

Дата заявки: 28-04-2016

The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.

CPC - классификация

A A6 A61 A61K A61K3 A61K39 A61K39/A61K39/3 A61K39/39 A61K39/395 A61P A61P1 A61P1/A61P1/0 A61P1/04 A61P1/1 A61P1/16 A61P13 A61P13/A61P13/1 A61P13/12 A61P17 A61P17/A61P17/0 A61P17/00 A61P19 A61P19/A61P19/0 A61P19/02 A61P19/04 A61P2 A61P21 A61P21/A61P21/0 A61P21/00 A61P21/04 A61P25 A61P25/A61P25/0 A61P25/00 A61P25/02 A61P29 A61P29/A61P29/0 A61P29/00 A61P3 A61P3/A61P3/0 A61P3/00 A61P37 A61P37/A61P37/0 A61P37/02 A61P37/06 A61P37/08 A61P5 A61P5/A61P5/0 A61P5/00 A61P7 A61P7/A61P7/0 A61P7/00 A61P7/06 A61P9 A61P9/A61P9/0 A61P9/00 C C0 C07 C07K C07K1 C07K14 C07K14/C07K14/0 C07K14/00 C07K16 C07K16/C07K16/0 C07K16/00 C07K16/2 C07K16/28 C07K16/283 C07K16/4 C07K16/46 C07K2 C07K23 C07K231 C07K2317 C07K2317/C07K2317/1 C07K2317/14 C07K2317/3 C07K2317/33 C07K2317/5 C07K2317/52 C07K2317/526 C07K2317/6 C07K2317/60 C07K2319 C07K2319/C07K2319/3 C07K2319/30

IPC - классификация

A A6 A61 A61P A61P2 A61P21 A61P21/A61P21/0 A61P21/04 A61P29 A61P29/A61P29/0 A61P29/00 A61P4 A61P43 A61P43/A61P43/0 A61P43/00 C C0 C07 C07K C07K1 C07K14 C07K14/C07K14/0 C07K14/00 C07K16 C07K16/C07K16/0 C07K16/00 C07K16/2 C07K16/28 C07K16/4 C07K16/46 C07K19 C07K19/C07K19/0 C07K19/00

Цитирование НПИ

Dall'Acqua et al., J. Immunol. 177:1129-1138, 2006.
European Search Report in Application No. 15785583.4, dated Nov. 7, 2017, 12 pages.
International Preliminary Report on Patentability for International Patent Application No. PCT/US2015/028926, dated Nov. 17, 2016 (12 pages).
International Search Report and Written Opinion for International Application No. PCT/US17/20519, dated Aug. 24, 2017, 17 pages.
International Search Report and Written Opinion for International Application No. PCT/US17/34084, dated Sep. 14, 2017, 19 pages.
International Search Report and Written Opinion for International Application No. PCT/US17/34087, dated Oct. 18, 2017, 20 pages.
International Search Report and Written Opinion for International Application No. PCT/US2015/028926, dated Oct. 28, 2015 (22 pages).
International Search Report and Written Opinion in International Application No. PCT/US2018/012488, dated May 25, 2018, 26 pages.
Kacskovics et al., Veterinary Immunology and Immunopathology 102:351-362, 2004.
Lund et al., The Journal of Immunology 157:4963-4969, 1996.
Mekhaiel et al., “Polymeric human Fc-fusion proteins with modified effector functions,” Scientific Reports, Aug. 2011, 1: 124 (11 pages).
Mimoto et al., “Novel asymmetrically engineered antibody Fc variant with superior FcyR binding affinity and specificity compared with afucosylated Fc variant,” mAbs, Feb. 2013, 5: 229-236.
Office Action in Israeli Application No. 247442, dated Jun. 3, 2018, 7 pages.
Ortiz et al., “Elucidating the interplay between IgG-Fc valency and FcgR actication for the design of immune complex inhibitors,” Science Translational Medicine, Nov. 16, 2016, 8:1-13.
Salfeld et al., Nature Biotech. 25(12): 1369-1372, 2007.
Shields et al., “High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcyR,” The Journal of Biological Chemistry, 2001, 276: 6591-6604.
Stavenhagen et al., “Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells in vitro and Controls Tumor Expansion in vivo via Low-Affinity Activating Fcγ Receptors,” Cancer Res, 2007, 67: 8882-8890.

Получить PDF